Fior Markets launched a study titled “Global Auto injectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis and Other Therapies), Type, End User, Region” and Global Forecast 2018-2025.

The global auto injectors market is expected to grow from USD 27.82 Billion in 2017 to USD 172.38 Billion by 2025 at a CAGR of 27.63% during the forecast period from 2018-2025. Preference over conventional devices as they provide improved drug delivery and enhanced efficiency in terms of drug delivery and increasing incidence of life-threatening allergic are increasing demand for injector device for instant treatment will lead to the growth of market in a couple of years.


Rheumatoid arthritis based segment is anticipated to grow with the highest CAGR of 29.31% in the forecast period

Therapy segment includes rheumatoid arthritis, multiple sclerosis, anaphylaxis, cardiovascular diseases, psoriasis and migraine. Rheumatoid arthritis based segment is anticipated to grow with the highest CAGR of 29.31% in the forecast period. Increase in the incidence of anaphylactic shock, rise and government’s support for allowing the marketing of the instrument in various locations is driving the growth of the market.

Hospital segment is held largest market share of 56.07% in 2017

End user segment is divided into segments such as homecare, and hospitals. Hospital segment held the largest market share of 56.07% in 2017. Proper diagnosis and treatment provided at hospitals will lead to the growth of segment in future.

Regional Segmentation Analysis:

The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. North America was valued around USD 13.68 Billion in 2017. Rise in the healthcare expenditure and readiness to take up novel products for emergency care and chronic & acute diseases are the propelling the growth of auto-injectors market in this region.


Competitive Analysis:

The major players of market include Biogen Idec, Inc., Antares Pharma, Inc., Becton, Dickinson and Company, Novartis International AG, Mylan, Inc., Pfizer, Inc., Unilife Corporation, Scandinavian Health Limited (SHL) Group, Ypsomed Holdings AG, Sanofi S. A., ELI Lilly and others. Auto-injectors companies are collaborating with other companies to manufacture more advanced and innovative products. For example, in 2016, Aptar Pharma entered into an agreement with Becton, Dickinson & Co. to develop auto-injectors devices to be used safely by patients. The two-step auto-injectors will be exclusively sold by Becton, Dickinson & Co. Technological advancements are playing major role in the growth of the market. For instance, in 2017, Kaleo Pharmaceutical launched supplemental new drug application (sNDA) named as – AUVI-Q (0.1mg). This drug was reviewed on a priority basis by the U.S. Food and Drug Administration (US FDA). AUVI-Q is the first known epinephrine auto-injector. It is designed to treat an allergic reactions especially in infants.

Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.